Mini-Focus Issue: CardiomyopathiesCase Report: Clinical CaseComprehensive Risk Management in Arrhythmogenic Cardiomyopathy Associated With Autosomal Dominant Carvajal Syndrome: Protecting Families
Graphical abstract
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Olivotto was supported by the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement 777204: “SILICOFCM - In Silico Trials for Drug Tracing the Effects of Sarcomeric Protein Mutations Leading to Familial Cardiomyopathy”; by the Italian Ministry of Health (“Left Ventricular Hypertrophy in Aortic Valve Disease and Hypertrophic Cardiomyopathy: Genetic Basis, Biophysical Correlates and Viral Therapy Models” (RF-2013-02356787) and NET-2011-02347173 (“Mechanisms and Treatment of Coronary Microvascular Dysfunction in Patients With Genetic or Secondary Left Ventricular Hypertrophy”); and by the Ente Cassa di Risparmio di Firenze (bando 2016) “Juvenile Sudden Cardiac Death: Just Know and Treat.” All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Case Reports author instructions page.